Dextromethorphan/quinidine regulatory update

FDA approved an NDA for Nuedexta dextromethorphan/quinidine to treat pseudobulbar affect (PBA). Avanir expects to launch Nuedexta in 1Q11. The company initially submitted the NDA for Nuedexta in 2005...